 HYDERABAD, India and PRINCETON, N.J.--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as Dr. Reddys today announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda capecitabine Tablets approved by the U.S. Food and Drug Administration USFDA. The Xeloda brand and generic had U.S. sales of approximately 90 million MAT for the most recent twelv 